Home > Dermatology > U.S. FDA declines to approve Amryt’s topical gel for rare skin diseases

U.S. FDA declines to approve Amryt’s topical gel for rare skin diseases


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Reuters - 28/02/2022 - Amryt Pharma said on Monday the U.S. Food and Drug Administration declined to approve the company's drug for the treatment of a group of rare skin diseases called epidermolysis bullosa. The agency has asked Amryt to submit additional data confirming effectiveness of the drug. The decision comes after the FDA had extended its review of the treatment, oleogel-S10, in November by three months to review additional analyses of data previously submitted by the company. The regulator had also asked for new information on the drug. Amryt said it intends to discuss with the FDA regarding the nature of data required to address the health regulator's concerns. Epidermolysis bullosa (EB) is a disease causing fragile skin that blisters and tears easily. Currently, there is no approved therapy for the condition. Treatment for EB has usually involved controlling symptoms by using and changing bandages as well as managing pain and itching with m...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on